What to Expect?
PharmaSynergyRx is known for creating a focused and tailored event that caters to companies pursuing co-development, partnerships, licensing, and commercial deals.
The event always goes beyond the ordinary, offering a comprehensive programme that includes a thoughtfully curated conference agenda, opportunities for informal networking, and structured meetings.
We are working to make your PharmaSynergyRx 2025 event interesting, useful and unique. Take a moment to read about what's in store for you in the next edition.
Product Portfolio Focus
* Primary, Niche, Branded, and Hybrid Generics, Value-Added Medicines (VAMs)
* Specialty, Biosimilars, and Hospital Products
* Legacy products
* New chemical entities (late stage)
* Technology Platforms: Dosage, Formulation, Delivery
1-2-1 Meetings & Networking
Networking and 1-2-1 meetings lie at the very core of our events.
As the event unfolds, you'll find the pre-scheduled time slots and content sessions seamlessly woven into the fabric of the day, ensuring that your agenda is personalised, leaving no room for missed opportunities.
Global BD&L Audience
We view our events as part of an ongoing journey to foster connections across global markets.
Our BD&L community includes companies with diverse portfolios in various therapeutic areas, creating a unique environment for continuous networking and collaboration.
Partnering Platform
Our partnering platform serves as the launchpad, allowing you to plan and schedule meetings ahead of time. Whether you're seeking that crucial partnership, investment, or collaboration, this digital gateway empowers you to curate a lineup of meaningful interactions.
These are just some of the companies that have confirmed their participation
Market Information & Presentations
We aim to provide you with various perspectives and strategic insights. In 2025, as always, our event will bring together the most interesting speakers who will explore diverse topics, including growth strategies, licensing and BD&L deal structures, opportunities for orphan drugs, biosimilars, and specialty products, and talk about the evolving landscape in emerging regions.